Your Genes Determine Half Your Lifespan: The Weizmann Study That Rewrites Longevity Science

A landmark study in Science reveals that genetics accounts for roughly 50% of variation in human lifespan, more than double what researchers believed for decades, and the implications for precision longevity medicine are profound.

Presented By Our Partners

For years, the prevailing message from longevity researchers, wellness practitioners, and public health officials has been consistent: your lifestyle matters more than your genes. Sleep well. Eat well. Move every day. The implicit promise underneath that message was reassuring in its democratic simplicity: biology is not destiny. What you do with your body trumps what you were born with.

A study published in Science in January 2026 by researchers at Israel’s Weizmann Institute of Science does not exactly overturn that message. But it complicates it significantly, and in ways that carry major consequences for how we understand aging, design longevity interventions, and counsel patients about their individual risk.

The finding: roughly 50% of the variation in human lifespan is attributable to genetics, once you remove deaths caused by extrinsic factors like accidents and infections from the equation. That figure is more than double the 20-25% estimated by most twin studies over the past several decades, and dramatically higher than the 6-10% suggested by more recent large-scale pedigree analyses that sparked a brief but influential wave of “genes don’t matter much” coverage in science media.

The research was led by doctoral student Ben Shenhar from the laboratory of Professor Uri Alon in the Molecular Cell Biology Department at the Weizmann Institute. Its central argument is methodological: previous heritability estimates were systematically wrong because they failed to separate deaths that genetics can influence from deaths that genetics cannot.

The Problem With How We’ve Been Measuring Genetic Influence on Lifespan

Heritability is a statistical concept describing the proportion of variation in a trait within a population that can be attributed to genetic differences. A heritability of 100% would mean that all variation in a trait, say height in a genetically diverse population with uniform nutrition, is explained by genetic differences. A heritability of 0% would mean genes play no role at all.

For most human traits, heritability sits somewhere between these extremes. Intelligence shows heritability around 50-80% in adults. Body mass index sits around 40-70%. Cardiovascular disease risk around 40-60%. But lifespan has long been treated as an outlier, with estimates clustering in the 20-25% range from classical twin studies and falling as low as 6% in genome-wide association studies using family pedigrees.

The Shenhar and Alon team identified a fundamental flaw in how those calculations were made: they lumped together all deaths regardless of cause. When a 22-year-old dies in a car accident, that death tells us almost nothing about the genetic architecture of aging. When a 25-year-old dies of cholera during an epidemic, same story. But both deaths entered previous heritability calculations as data points on the same footing as deaths from cancer, heart failure, and neurodegeneration at age 85.

This matters because extrinsic mortality, deaths caused by environmental hazards, accidents, and infectious disease, has been historically high, particularly in older data. When a substantial fraction of deaths in your twin dataset have nothing to do with biological aging, your estimate of how much genes influence aging gets diluted. The signal gets buried in noise.

To correct for this, the researchers developed a mathematical model that separates intrinsic mortality (driven by internal biological aging processes) from extrinsic mortality. They then applied this model to three large twin registries from Sweden and Denmark. Crucially, one of those datasets had never been used in this context before: a cohort of twins who were raised apart. This dataset is extraordinarily valuable because it allows researchers to isolate genetic effects from shared childhood environments, which can themselves inflate heritability estimates in twins raised together.

The Numbers: 50% and What It Actually Means

When the Weizmann team corrected for extrinsic mortality across all three datasets, heritability estimates consistently plateaued at approximately 50%. The finding was robust across different analytical approaches and held whether researchers used identical twins, fraternal twins, or twins raised in separate households.

This does not mean that half your lifespan is “predetermined” in any fatalistic sense. Heritability is a population-level statistic, not an individual-level prediction. It tells you how much of the variation between people is explained by their genetic differences under current environmental conditions. If everyone in a population had exactly the same lifestyle, diet, and environmental exposures, the heritability of lifespan would likely rise further, because all remaining variation would have to come from somewhere, and genes would account for more of it. Conversely, if genetic editing became so precise that it could equalize everyone’s longevity-relevant biology, heritability would fall toward zero.

The researchers were careful to underscore this nuance. “Environment is still super important, and people should try to optimize their lifestyle as much as they can,” the team noted in communications around the paper. A genetic propensity toward longevity does not protect you from chronic stress, sedentary behavior, poor nutrition, or sleep deprivation. And a genetic architecture that predisposes toward earlier mortality does not condemn you to it.

What the 50% figure does tell us is that for about half the variation we observe in how long people live, genes provide a meaningful explanation. That explanation is worth pursuing, because understanding which genes are involved, and what they do, could unlock entirely new classes of longevity interventions.

The Disease-Specific Findings: Dementia Heritability Is Startling

One of the more striking sub-findings of the paper concerns specific causes of death. The Weizmann team did not just calculate overall lifespan heritability. They also examined how heritability varied by cause of death and by age.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Their analysis found that dementia mortality, meaning the contribution of dementia to dying before your time, carries a heritability of approximately 70% up to age 80. That figure is substantially higher than the heritability of dying from cancer or cardiovascular disease, which came in at roughly 30-40% by comparison.

This finding has immediate clinical relevance. It suggests that brain aging, specifically the pathways leading to neurodegenerative decline and dementia, may be more genetically driven than we previously recognized. We already know that APOE4 carrier status significantly elevates Alzheimer’s risk, and that rare genetic variants in genes like PSEN1 and PSEN2 cause early-onset Alzheimer’s with near-deterministic effect. But those variants account for only a fraction of dementia cases. The 70% dementia heritability figure implies that there is a broad landscape of common genetic variants, each contributing a small effect, that collectively shape neurological aging trajectories in profound ways that current medicine has not yet fully mapped.

For cardiovascular disease and cancer, the lower heritability estimates are consistent with what researchers have long understood: environmental and behavioral factors play a proportionally larger role in these diseases, which is precisely why interventions targeting blood pressure, cholesterol, smoking, physical activity, and diet have been so effective at reducing mortality from heart disease over the past 60 years.

What Longevity Genes Might Be Doing

If genetics accounts for roughly half of lifespan variation, the next logical question is: which genes, and what exactly are they doing?

Research over the past two decades has identified several promising candidates. FOXO3 variants have been consistently associated with exceptional longevity across populations from Japan to Germany to Hawaii. FOXO3 is a transcription factor in the insulin and IGF-1 signaling pathway, one of the most conserved longevity pathways across species. Its variants appear to influence how efficiently cells manage oxidative stress, repair DNA damage, and regulate apoptosis.

SIRT6, another longevity-associated gene, codes for a protein involved in DNA repair and genome stability. Research published in 2021 and cited in subsequent longevity literature found that a rare SIRT6 variant identified in centenarians enhances interaction with Lamin A, a structural protein in the nuclear membrane, providing unusual protection against the genome instability that accumulates during aging.

APOE continues to dominate neurological longevity research. The APOE2 variant appears protective against both cardiovascular disease and Alzheimer’s, while APOE4, carried by roughly 25% of the population, elevates risk for both. The Weizmann team’s 70% dementia heritability figure suggests that the APOE landscape, and the broader genetic architecture of lipid metabolism and neuroinflammation, may be even more central to brain aging than current clinical practice recognizes.

The TERT gene, which codes for telomerase reverse transcriptase and governs telomere maintenance, also emerges consistently in longevity genomics research. Variants that preserve telomere length tend to associate with longer healthspans, though the relationship between telomere biology and lifespan is complex and not simply linear.

Beyond individual genes, researchers are increasingly interested in polygenic scores, composite measures that aggregate the effects of thousands of common genetic variants to generate individual-level predictions about disease risk, biological age, and longevity trajectory. The Weizmann finding strengthens the scientific rationale for investing in these tools, because a 50% heritability figure means there is substantial genetic signal to detect if you build models sensitive enough to find it.

The Centenarian Blueprint and What It Reveals

Researchers studying extreme longevity have long recognized that the oldest humans are not simply people who did everything right. Many centenarians smoked, drank, ate erratically, and exercised little by conventional standards. Their exceptional longevity appears to reflect genuine biological protection, an architecture that buffers them against the diseases and cellular deterioration that kill most people decades earlier.

Studies of supercentenarian genetics, including ongoing work cataloging the rare variants found in people who live past 110, are beginning to reveal what that protection looks like at the molecular level. Common themes include enhanced DNA damage response, more efficient proteostasis (the machinery that keeps misfolded proteins from accumulating), better-regulated inflammatory signaling, and more resilient mitochondrial function.

A comprehensive multiomics analysis of the world’s oldest validated living person published in recent longevity literature found patterns suggesting that exceptional longevity involves not just individual gene variants but systemic differences in how biological processes coordinate across tissues and time. The Weizmann team’s 50% heritability figure implies that these systemic differences have a substantial genetic foundation, one that future genomic medicine can eventually learn to map and potentially replicate through targeted intervention.

The Lifestyle-Genetics Integration: A More Sophisticated Framework

The most important thing this research does not say is that lifestyle choices are irrelevant. The logic of longevity science has never been either/or. It has always operated in a space where genetic predispositions establish probabilities and behavioral choices move you along those probability distributions.

A person carrying favorable longevity variants in FOXO3, APOE, and TERT who nonetheless smokes two packs a day, maintains a sedentary lifestyle, and sleeps five hours a night will not achieve their genetic longevity potential. Conversely, a person with less favorable genetic architecture who optimizes sleep, maintains a Mediterranean-style whole food diet, builds consistent cardiovascular fitness and resistance training into their routine, and manages chronic stress through breathwork and community connection may substantially outperform what their raw genetic profile would predict.

This integration, gene-informed but behavior-driven, is precisely where longevity medicine is headed. The emerging field of precision healthspan uses polygenic risk scores, epigenetic clocks, and biomarker panels to give individuals individualized risk profiles, and then tailors interventions, dietary strategies, exercise protocols, pharmaceutical candidates, and monitoring intensity, based on those profiles rather than applying one-size-fits-all population guidelines.

The Weizmann study’s 50% heritability finding makes the genetic half of that framework more defensible. It confirms that there is enough genetic signal in lifespan to be clinically meaningful, which in turn justifies the investment in better genomic tools, larger biobank datasets, and more sophisticated analytical methods for translating genetic information into actionable health intelligence.

Implications for Drug Discovery and Preventive Medicine

Higher lifespan heritability has direct consequences for pharmaceutical research. If genes account for half of lifespan variation, then the biological pathways those genes regulate are strong candidates for drug targets. Identifying the molecular mechanisms through which longevity-associated variants confer their benefits points toward compounds that could potentially replicate or amplify those effects pharmacologically.

This is the logic behind several of the most promising longevity pharmacology programs currently in development: rapamycin analogs targeting the mTOR pathway, which sits downstream of several longevity-associated genetic variants; metformin and the TAME (Targeting Aging with Metformin) trial; senolytics like dasatinib and quercetin targeting the senescent cell accumulation that longevity-associated variants appear to slow; and NAD-plus precursors like NMN and NR addressing the mitochondrial and DNA repair pathways in which longevity genes are heavily represented.

On the preventive medicine side, higher heritability justifies more aggressive family history collection and genetic screening in clinical practice. If dementia carries 70% heritability, knowing your family’s neurological history and obtaining APOE genotyping and potentially broader polygenic risk profiling becomes a rational clinical priority for anyone interested in optimizing their cognitive longevity trajectory. It also means that interventions targeting dementia-specific pathways, whether lifestyle-based like the FINGER protocol or pharmacological, should be deployed more aggressively in people with high genetic risk long before clinical symptoms emerge.

What This Means for You

The Weizmann finding does not change what optimal longevity practice looks like on a day-to-day basis. The foundations of the Five Pillars, consistent resistance and cardiovascular training, whole-food nutrition that stabilizes blood sugar and supports the gut microbiome, seven to nine hours of quality sleep, breathwork and stress regulation, and strong social and community connection, remain the most evidence-backed levers available to any individual regardless of their genetic profile.

What the 50% heritability finding does change is the clinical conversation that should surround those foundations. Family history of exceptional longevity is an asset worth knowing about and understanding mechanistically. Family history of early dementia, cardiovascular disease, or metabolic dysfunction is a signal that should prompt earlier, more aggressive preventive action rather than waiting for symptoms to emerge.

For those with access to genomic testing, understanding your APOE status, your polygenic risk scores for cardiovascular and neurodegenerative disease, and your current epigenetic age relative to chronological age gives you a map for which pillars to prioritize most aggressively. Someone with APOE4 carrier status should treat sleep quality and aerobic fitness as near-non-negotiable given their elevated neurological risk. Someone with strong family history of metabolic disease should treat blood sugar regulation and resistance training as primary, not secondary, health investments.

Perhaps most importantly, the 50% heritability finding should be read as a call to action for genetic science, not as a reason for genetic fatalism. Half of lifespan variation being genetic means there is a large, coherent body of biology to understand and eventually influence. It means the project of longevity medicine has more scientific foundation beneath it than skeptics have argued. And it means that the next decade of genomic research, polygenic risk tool development, and precision intervention design has a more compelling justification than ever before.

Your genes are not your destiny. But they are a map worth reading.

The Bottom Line

A landmark study from the Weizmann Institute of Science, published in Science in January 2026, has established that human lifespan heritability is approximately 50% when deaths from accidents, infections, and other extrinsic causes are properly excluded from the analysis. This figure is more than double previous estimates, validates the scientific rationale for precision longevity medicine, and identifies dementia mortality as carrying an especially high genetic load of around 70%. The finding does not diminish the power of lifestyle choices but recalibrates how clinicians and researchers should think about genetic risk, screening, and the design of targeted longevity interventions. Understanding your genetic architecture is becoming as clinically important as understanding your cholesterol panel, and this study is a significant scientific step toward making that understanding routine.

Study reference: Shenhar B, Alon U. “Heritability of intrinsic human life span is about 50% when confounding factors are addressed.” Science, January 2026. DOI: 10.1126/science.adz1187

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.